Direct medical costs attributable to acute myocardial infarction and ischemic stroke in cohorts with atherosclerotic conditions

Cerebrovascular Diseases

Volumn 18, Issue 1, 2004, Pages 8-15

  Sloss, Elizabeth M ^a   Wickstrom, Steven L ^a   McCaffrey, Daniel F ^a   Garber, Steven ^a   Rector, Thomas S ^a   Levin, Regina A ^a   Guzy, Peter M ^a   Gorelick, Philip B ^a   Dake, Michael D ^a   Vickrey, Barbara G ^a  

^a RAND CORPORATION   (United States)

Author keywords

Acute myocardial infarction, costs; Costs, acute myocardial infarction stroke; Secondary atherosclerotic events, costs; Stroke, costs

Indexed keywords

ACUTE HEART INFARCTION; ADULT; AGED; ARTERY DISEASE; ARTICLE; ATHEROSCLEROSIS; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; COST EFFECTIVENESS ANALYSIS; FEMALE; GOVERNMENT; HEALTH INSURANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; MEDICARE; PRIORITY JOURNAL; PRIVATE HEALTH INSURANCE; PUBLIC HEALTH INSURANCE; UNITED STATES;

AGED; ARTERIOSCLEROSIS; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; COHORT STUDIES; FEMALE; HEALTH CARE COSTS; HUMANS; INSURANCE, HEALTH; MALE; MEDICARE; MIDDLE AGED; MYOCARDIAL INFARCTION;

EID: 3042588659     PISSN: 10159770     EISSN: None     Source Type: Journal    
DOI: 10.1159/000078602     Document Type: Article

References (35)

1. Vickrey BG, Rector TS, Wickstrom SL, Guzy PM, Sloss EM, Gorelick PB, Garber S, McCaffrey DF, Dake MD, Levin RA: Occurrence of secondary ischemic events among persons with atherosclerotic vascular disease. Stroke 2002;33:901-906.
2. Khoury Z, Schwartz R, Gottlieb S, Chenzbraun A, Stern S, Keren A: Relation of coronary artery disease to atherosclerotic disease in the aorta, carotid, and femoral arteries evaluated by ultrasound. Am J Cardiol 1997;80:1429-1433.
3. Brass LM, Hartigan PM, Page WF, Concato J: Importance of cerebrovascular disease in studies of myocardial infarction. Stroke 1996;27:1173-1176.
4. CAPRIE Steering Committee: A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet 1996;348:1329-1339.
5. Murabito JM, D'Agostino RB, Silbershatz H, Wilson WF: Intermittent claudication: A risk profile from the Framingham Heart Study. Circulation 1997;96:44-49.
6. Taylor TN, Davis PH, Torner JC, Holmes J, Meyer JW, Jacobson MF: Lifetime cost of stroke in the United States. Stroke 1996;27:1459-1466.
7. Taylor TN: The medical economics of stroke. Drugs 1997;54(suppl):S51-S57.
8. Hay JW, Wittels EH, Gotto AM Jr: An economic evaluation of lovastatin for cholesterol lowering and coronary artery disease reduction. Am J Cardiol 1991;67:789-796.
9. Ashraf T, Hay JW, Pitt B, Wittels E, Crouse J, Davidson M, Furberg CD, Radican L: Cost-effectiveness of pravastatin in secondary prevention of coronary artery disease. Am J Cardiol 1996;78:409-414.
10. Mantovani LG, Belisari A, Szucs TD: Captopril in the management of patients after acute myocardial infarctions: A cost-effectiveness analysis in Italy. Pharmacol Res 1998;37:345-351.
11. Muls E, Van Ganse E, Closon MC: Cost-effectiveness of pravastatin in secondary prevention of coronary heart disease: Comparison between Belgium and the United States of a projected risk model. Atherosclerosis 1998;137(suppl):S111-S116.
12. Marissal JP, Selke B, Lebrun T: Economic assessment of the secondary prevention of ischaemic events with lysine acetylsalicylate. Pharmacoeconomics 2000;18:185-200.
13. Wittels EH, Hay JW, Gotto AM Jr: Medical costs of coronary artery disease in the United States. Am J Cardiol 1990;65:432-440.
14. Scott WG, White HD, Scott HM: Cost of coronary heart disease in New Zealand. N Z Med J 1993;106:347-349.
15. Russell MW, Huse DM, Drowns S, Hamel EC, Hartz SC: Direct medical costs of coronary artery disease in the United States. Am J Cardiol 1998;81:1110-1115.
16. Topol EJ, Ellis SG, Cosgrove DM, Bates ER, Muller DW, Schork NJ, Schork MA, Loop FD: Analysis of coronary angioplasty practice in the United States with an insurance-claims data base. Circulation 1993;87:1489-1497.
17. Hlatky MA, Rogers WJ, Johnstone I, Boothroyd D, Brooks MM, Pitt B, Reeder G, Ryan T, Smith H, Whitlow P, Wiens R, Mark DB: Medical care costs and quality of life after randomization to coronary angioplasty or coronary bypass surgery. N Engl J Med 1997;336:92-99.
18. Taylor GJ, Mikell FL, Moses HW, Dove JT, Katholi RE, Malik SA, Markwell SJ, Korsmeyer C, Schneider JA, Wellons HA: Determinants of hospital charges for coronary artery bypass surgery: The economic consequences of postoperative complications. Am J Cardiol 1990;65:309-313.
19. SAS Institute: SAS OnlineDoc®, version 8. Cary, SAS Institute, 1999.
20. Agency for Healthcare Research and Quality: Clinical Classifications Software (CCS), 1999. Available via http://www.ahrq.gov/data/hcup/ ccs/ccsusrqd.doc.
21. Bang H, Tsiatis AA: Estimating medical costs with censored data. Biometrika 2000;82:329-343.
22. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
23. Efron B, Tibshirani RJ: An Introduction to the Bootstrap. New York, Chapman & Hall, 1993.
24. Charles ED, Wayne JB, Oberman A, Reed BA, Haynie C, Kouchoukos NT, Rogers WJ, Russell RO: Costs and benefits associated with treatment for coronary artery disease. Circulation 1982;66(5 Pt 2):III87-III90.
25. Ellis SG, Brown KJ, Ellert R, Howell GL, Miller DP, Flowers NM, Ott PA, Keys T, Loop FD, Topol EJ: Cost of cardiac care in the three years after coronary catheterization in a contained care system: Critical determinants and implications. J Am Coll Cardiol 1998;31:1306-1313.
26. Ellis SG, Miller DP, Brown KJ, Omoigui N, Howell GL, Kutner M, Topol EJ: In-hospital cost of percutaneous coronary revascularization: Critical determinants and implications. Circulation 1995;92:741-747.
27. Hlatky MA, Lipscomb J, Nelson C, Califf RM, Pryor D, Wallace AG, Mark DB: Resource use and cost of initial coronary revascularization: Coronary angioplasty versus coronary bypass surgery. Circulation 1990;82(5 Suppl):IV208-IV213.
28. Ray GT, Collin F, Lieu T, Fireman B, Colby CJ, Quesenberry CP, Van Den Eden SK, Selby JV: The cost of health conditions in a health maintenance organization. Med Care Res Rev 2000;57:92-109.
29. Mark DB, Talley JD, Topol EJ, Bowman L, Lam LC, Anderson KM, Jollis JG, Cleman MW, Lee KL, Aversano T, Untereker WJ, Davidson-Ray L, Califf RM: Economic assessment of platelet glycoprotein IIb/IIIa inhibition for prevention of ischemic complications of high-risk coronary angioplasty. Circulation 1996;94:629-635.
30. Jollis JG, Ancukiewicz M, DeLong ER, Pryor DB, Muhlbaier LH, Mark DB: Discordance of databases designed for claims payment versus clinical information systems: Implications for outcomes research. Ann Intern Med 1993;119:844-850.
31. Ellerbeck EF, Jencks SF, Radford MJ, Kresowik TF, Craig AS, Gold JA, Krumholz HM, Vogel RA: Quality of care for Medicare patients with acute myocardial infarction: A four state pilot study from the cooperative cardiovascular project. JAMA 1995;273:1509-1514.
32. Soumerai SB, McLaughlin TJ, Spiegelman D, Hertzmark E, Thibault G, Goldman L: Adverse outcomes of underuse of beta-blockers in elderly survivors of acute myocardial infarction. JAMA 1997;277:115-121.
33. Fisher ES, Whaley FS, Krushat WM, Malenka DJ, Fleming C, Baron JA, Hsia DC: The accuracy of Medicare's hospital claims data: Progress has been made, but problems remain. Am J Public Health 1992;82:243-248.
34. Iezzoni LI, Burnside S, Sickles L, Moskowitz MA, Sawitz E, Levine PA: Coding of acute myocardial infarction: Clinical and policy implications. Ann Intern Med 1988;109:745-751.
35. Benesch C, Witter DM, Wilder AL, Duncan PW, Samsa GP, Matchar DB: Inaccuracy of the International Classification of Disease (ICD-9-CM) in identifying the diagnosis of ischemic cerebrovascular disease. Neurology 1997;49:660-664.